ProKidney Corp. (NASDAQ:PROK) Q3 2023 Results Conference Call November 14, 2023 8:00 AM ET
Company Participants
Dr. Glenn Schulman - SVP of IR
Pablo Legorreta - Chairman of Board
Dr. Tim Bertram - Co-Founder and Member of Scientific Advisory Board
Dr. Bruce Culleton - Chief Executive Officer
Conference Call Participants
Yigal Nochomovitz - Citi
Justin Zelin - BTIG
Jonathan Miller - Evercore
Jason Gerberry - Bank of America
Operator
Good morning, ladies and gentlemen, and welcome to the ProKidney Corporate Update Conference Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded.
At this time, it is now my pleasure to introduce your host, Dr. Glenn Schulman, Senior Vice President of Investor Relations. Please go ahead, sir.
Dr. Glenn Schulman
Thank you, Rob. Good morning, everyone, and welcome to ProKidney's corporate update conference call. Yesterday evening, after the market closed, we issued a press release that provided several corporate updates, and then this morning released our third quarter 2023 financial results, press release and 10-Q filings. Please note a replay of today's call will be available on the Investors section of our website approximately one after -- one hour after its completion.
Joining us on the call this morning are ProKidney's Chairman of the Board, Pablo Legorreta; ProKidney's Co-Founder and member of the Scientific Advisory Board, Dr. Tim Bertram; and ProKidney's new Chief Executive Officer, Dr. Bruce Culleton. Following some introductory comments by Pablo and Dr. Bertram, prepared remarks by Dr. Culleton on REACT-002, interim results and the clinical development program, we will open up the call for your questions.
Also joining us today on the call is our Chief Financial Officer, James Coulston; and our Chief Regulatory Officer, Dr. Darin Weber. Before we begin, I'd just like to remind everyone that during this conference call, we will be making forward-looking statements about the Company. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those forecasted.
Actual results could differ materially by those stated or implied by these forward-looking statements due to risks and uncertainties associated with the Company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release, 10-Q filing and our other SEC filings, including our annual report on Form 10-K and subsequent filings.
Please also note that these forward-looking statements reflect our opinions only as of today, November 14, 2023, and except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements to lay or future events.